– A single intravitreal administration of PER-001 improved both visual function and anatomic structure compared to control at 24 weeks – – These data support the potential of PER-001 as the first ...
Following a request for judicial review by drugmakers Bayer and Novartis, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) issued a statement clarifying that Roche's Avastin ...
TOKYO, Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S.
The Agency is now requiring the submission of confirmatory efficacy data to support the application. The Food and Drug Administration (FDA) has issued another Complete Response Letter (CRL) to Outlook ...
NORTHBROOK, Ill., March 26, 2024 /PRNewswire/ -- Iveric Bio, An Astellas Company (TSE: 4503, President and CEO: Naoki Okamura, "Astellas"), today announced the U.S. Centers for Medicare and Medicaid ...
STOCKHOLM -- Two VEGF-targeting gene therapies for neovascular age-related macular degeneration (nAMD) substantially reduced treatment burden while preserving visual acuity, according to results ...
Over 2 years, only a slight increased incidence of choroidal neovascularization was observed for IZERVAY pooled vs. sham; in year 2, incidence of CNV was similar for IZERVAY EOM vs. sham "GA is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results